Details

Autor(en) / Beteiligte

• Boissel, Nicolas
• Renneville, Aline
• Leguay, Thibaut
• Lefebvre, Pascale Cornillet
• Recher, Christian
• Lecerf, Thibaud
• Delabesse, Eric
• Berthon, Céline
• Blanchet, Odile
• Prebet, Thomas
• Pautas, Cécile
• Chevallier, Patrice
• Leprêtre, Stéphane
• Girault, Stéphane
• Bonmati, Caroline
• Guièze, Romain
• Himberlin, Chantal
• Randriamalala, Edouard
• Preudhomme, Claude
• Jourdan, Eric
• Dombret, Hervé
• Ifrah, Norbert

Titel

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

Ist Teil von

• Haematologica (Roma), 2015-06, Vol.100 (6), p.780-785

Ort / Verlag

Italy

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• Core-binding factor acute myeloid leukemia is a favorable acute myeloid leukemia subset cytogenetically defined by t(8;21) or inv(16)/t(16;16) rearrangements, disrupting RUNX1 (previously CBFA/AML1) or CBFB transcription factor functions. The receptor tyrosine kinase KIT is expressed in the vast majority of these acute myeloid leukemias and frequent activating KIT gene mutations have been associated with a higher risk of relapse. This phase II study aimed to evaluate dasatinib as maintenance therapy in patients with core-binding factor acute myeloid leukemia in first hematologic complete remission, but at higher risk of relapse due to molecular disease persistence or recurrence. A total of 26 patients aged 18-60 years old previously included in the CBF-2006 trial were eligible to receive dasatinib 140 mg daily if they had a poor initial molecular response (n=18) or a molecular recurrence (n=8). The tolerance of dasatinib as maintenance therapy was satisfactory. The 2-year disease-free survival in this high-risk population of patients was 25.7%. All but one patient with molecular recurrence presented subsequent hematologic relapse. Patients with slow initial molecular response had a similar disease-free survival when treated with dasatinib (40.2% at 2 years) or without any maintenance (50.0% at 2 years). The disappearance of KIT gene mutations at relapse suggests that clonal devolution may in part explain the absence of efficacy observed with single-agent dasatinib in these patients (n. EudraCT: 2006-006555-12).